Poteligeo 20 MG/5 ML vial 5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCFL6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $42,094
Award facts
- Contract value 100% obligated
- $42,094.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $42,094.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Poteligeo (mogamulizumab) 20 mg/5 ml vials. The delivery order, awarded on December 3, 2025, with an ultimate completion date of December 24, 2025, carries no set-aside designation, indicating the award was made through unrestricted competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceutical products to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a critical pharmaceutical supplier within the federal military medical supply chain, having received numerous delivery orders from the Defense Logistics Agency since October 2025. The company's comprehensive product portfolio spans branded and generic prescription medications, specialty pharmaceuticals, biologics, and medical consumables, positioning it to support the diverse pharmaceutical requirements of DoD healthcare operations globally. With its established performance record and expertise in distributing oncology treatments, immunosuppressants, emergency medications, and routine pharmaceuticals, DMS Pharmaceutical Group continues to serve as a key vendor supporting military healthcare logistics and operational readiness.
Quick answers
Who was awarded contract SPE2DR26FCFL6?
SPE2DR26FCFL6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FCFL6 worth?
The government has obligated $42,094 on SPE2DR26FCFL6.
Is contract SPE2DR26FCFL6 an order under another contract?
Yes. SPE2DR26FCFL6 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFL6 competed?
The extent of competition for SPE2DR26FCFL6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award